U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C25H30N8O4
Molecular Weight 506.5569
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ROBLITINIB

SMILES

COCCNC1=CC(NC(=O)N2CCCC3=CC(CN4CCN(C)CC4=O)=C(C=O)N=C23)=NC=C1C#N

InChI

InChIKey=BHKDKKZMPODMIQ-UHFFFAOYSA-N
InChI=1S/C25H30N8O4/c1-31-7-8-32(23(35)15-31)14-18-10-17-4-3-6-33(24(17)29-21(18)16-34)25(36)30-22-11-20(27-5-9-37-2)19(12-26)13-28-22/h10-11,13,16H,3-9,14-15H2,1-2H3,(H2,27,28,30,36)

HIDE SMILES / InChI

Description
Curator's Comment: The description was created based on several sources, including https://encrypted.google.com/patents/WO2015059668A1

FGF-401 is an inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon administration, FGF401 binds to and inhibits the activity of FGFR4, which leads to an inhibition of tumor cell proliferation in FGFR4-overexpressing cells. FGFR4 is a receptor tyrosine kinase upregulated in certain tumor cells and involved in tumor cell proliferation, differentiation, angiogenesis, and survival. FGF-401 is an FGFR4 inhibitor in phase I/II clinical studies at Novartis for the treatment of positive FGFR4 and KLB expression solid tumors and hepatocellular carcinoma.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
7.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Sourcing

Sourcing

Vendor/AggregatorIDURL
Patents

Patents

Sample Use Guides

Unknown
Route of Administration: Oral
The effect of compounds (FGF-401) on cell proliferation is assessed using HuH-7 hepatocellular carcinoma cells obtained from the Japanese Collection of Research Bioresources Cell Bank (Cat# JCRB0403) and cultured in the vendor-recommended medium (DMEM high glucose (Amimed Cat# 1 -26F01 -I), 10% foetal calf serum (Invitrogen Cat# 16140-071 ), 1 mM sodium pyruvate (Amimed Cat# 5-60F00-H), 1x Penicillin/Streptomycin (Amimed Cat# 4-01 F00-H)) at 37°C in a humidified 5% C02 incubator. Specifically, 5000 cells/well were seeded in 96-well tissue culture plates (TPP Cat# 92696) in a total media volume of 100 μΙ/well and increasing compound dilutions or DMSO were added 24 hours thereafter in triplicates. 72 hours after compound addition, cells were fixed by adding 25 [ Uwe\\ of 20% glutaraldehyde (Sigma Aldrich Cat# G400-4) and incubated for 10 minutes at room temperature. Cells were washed three times with H20, 200 [ Uwe\\ and stained with 100 [ Uwe\\ 0.05% methylene blue (ABCR GmbH Cat# AB1 17904) for 10 minutes at room temperature. Cells were washed 3 times with H20, 200 ML/well and then lysed by adding 200 ML/well of 3% HCI (Fluka Cat# 84422) for 30 minutes at room temperature with shaking. Optical density was measured at A650 nm.
Name Type Language
ROBLITINIB
INN  
Official Name English
roblitinib [INN]
Common Name English
Roblitinib [WHO-DD]
Common Name English
FGF-401
Code English
FGF401
Code English
Code System Code Type Description
CAS
1708971-55-4
Created by admin on Sat Dec 16 10:01:55 GMT 2023 , Edited by admin on Sat Dec 16 10:01:55 GMT 2023
PRIMARY
PUBCHEM
118036971
Created by admin on Sat Dec 16 10:01:55 GMT 2023 , Edited by admin on Sat Dec 16 10:01:55 GMT 2023
PRIMARY
ChEMBL
CHEMBL3545293
Created by admin on Sat Dec 16 10:01:55 GMT 2023 , Edited by admin on Sat Dec 16 10:01:55 GMT 2023
PRIMARY
FDA UNII
M64JF6WMSA
Created by admin on Sat Dec 16 10:01:55 GMT 2023 , Edited by admin on Sat Dec 16 10:01:55 GMT 2023
PRIMARY
INN
10760
Created by admin on Sat Dec 16 10:01:55 GMT 2023 , Edited by admin on Sat Dec 16 10:01:55 GMT 2023
PRIMARY
SMS_ID
100000181188
Created by admin on Sat Dec 16 10:01:55 GMT 2023 , Edited by admin on Sat Dec 16 10:01:55 GMT 2023
PRIMARY
NCI_THESAURUS
C120102
Created by admin on Sat Dec 16 10:01:55 GMT 2023 , Edited by admin on Sat Dec 16 10:01:55 GMT 2023
PRIMARY